Terms: = Leukemia AND PR, PGR, progesterone receptor AND Clinical Outcome
21 results:
1. Low serum albumin level deteriorates prognosis in azacitidine-treated myelodysplastic syndromes patients - results of the PALG study 'PolAZA'.
Mądry K; Lis K; Tukiendorf A; Szwedyk P; Kapelko-Słowik K; Subocz E; Gołos A; Makowska W; Masternak A; Kopińska A; Czemerska M; Zawadzka-Leska S; Rusicka P; Drozd-Sokołowska J; Wiater E; Hołojda J; Pogłódek B; Centkowski P; Waszczuk-Gajda A; Machowicz R; Hałka J; Czerw T; Basak G; Dwilewicz-Trojaczek J
Hematology; 2021 Dec; 26(1):556-564. PubMed ID: 34384334
[TBL] [Abstract] [Full Text] [Related]
2. Rebound lymphocytosis in a patient with chronic lymphocytic leukemia after cessation of a CDK 4/6 inhibitor for concomitant breast cancer.
Doucette K; Lai C; Pohlmann PR
Breast J; 2020 Oct; 26(10):2031-2033. PubMed ID: 32639043
[TBL] [Abstract] [Full Text] [Related]
3. Heavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients.
Michallet M; Chapuis-Cellier C; Dejoie T; Lombard C; Caillon H; Sobh M; Moreau P; Attal M; Avet-Loiseau H
Leukemia; 2018 Feb; 32(2):376-382. PubMed ID: 28663581
[TBL] [Abstract] [Full Text] [Related]
4. Minimal residual disease is an independent predictor for 10-year survival in CLL.
Kwok M; Rawstron AC; Varghese A; Evans PA; O'Connor SJ; Doughty C; Newton DJ; Moreton P; Hillmen P
Blood; 2016 Dec; 128(24):2770-2773. PubMed ID: 27697770
[TBL] [Abstract] [Full Text] [Related]
5. MLF1IP is correlated with progression and prognosis in luminal breast cancer.
Huang DP; Luo RC
Biochem Biophys Res Commun; 2016 Sep; 477(4):923-926. PubMed ID: 27378428
[TBL] [Abstract] [Full Text] [Related]
6. [Improved clinical outcome of acute myeloid leukemia with FLT3-ITD mutation treated with sorafenib].
Gu B; Chen GH; Shen HJ; Ma X; Fu CC; Han Y; Tang XW; Miao M; Qiu HY; Sun AN; Wu DP
Zhonghua Nei Ke Za Zhi; 2016 Apr; 55(4):293-7. PubMed ID: 27030618
[TBL] [Abstract] [Full Text] [Related]
7. Treatment with 5-Azacytidine improves clinical outcome in high-risk MDS patients in the 'real life' setting: A single center observational study.
Papageorgiou SG; Vasilatou D; Kontos CK; Foukas P; Kefala M; Ioannidou ED; Bouchla A; Bazani E; Dimitriadis G; Pappa V
Hematology; 2016 Jan; 21(1):34-41. PubMed ID: 26218077
[TBL] [Abstract] [Full Text] [Related]
8. Immunotherapy with the trifunctional anti-CD20 x anti-CD3 antibody FBTA05 (Lymphomun) in paediatric high-risk patients with recurrent CD20-positive B cell malignancies.
Schuster FR; Stanglmaier M; Woessmann W; Winkler B; Siepermann M; Meisel R; Schlegel PG; Hess J; Lindhofer H; Borkhardt A; Buhmann R
Br J Haematol; 2015 Apr; 169(1):90-102. PubMed ID: 25495919
[TBL] [Abstract] [Full Text] [Related]
9. [Comparative analysis of decitabine combined with DAG regimen and other regimens in treatment of refractory/relapsed acute myeloid leukemia].
Hao J; Wang L; Wang Y; Liu Z; Gu X; Liu J; Li L; Duan Y; Chen Y; Zhao W; Shen Z
Zhonghua Xue Ye Xue Za Zhi; 2014 Jun; 35(6):481-5. PubMed ID: 24985167
[TBL] [Abstract] [Full Text] [Related]
10. Expression of RUNX1 correlates with poor patient prognosis in triple negative breast cancer.
Ferrari N; Mohammed ZM; Nixon C; Mason SM; Mallon E; McMillan DC; Morris JS; Cameron ER; Edwards J; Blyth K
PLoS One; 2014; 9(6):e100759. PubMed ID: 24967588
[TBL] [Abstract] [Full Text] [Related]
11. A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia.
Burke MJ; Lamba JK; Pounds S; Cao X; Ghodke-Puranik Y; Lindgren BR; Weigel BJ; Verneris MR; Miller JS
Am J Hematol; 2014 Sep; 89(9):889-95. PubMed ID: 24891274
[TBL] [Abstract] [Full Text] [Related]
12. Genome-wide single-nucleotide polymorphism array-based karyotyping in myelodysplastic syndrome and chronic myelomonocytic leukemia and its impact on treatment outcomes following decitabine treatment.
Yi JH; Huh J; Kim HJ; Kim SH; Kim SH; Kim KH; Do YR; Mun YC; Kim H; Kim MK; Kim HJ; Kim T; Kim DD
Ann Hematol; 2013 Apr; 92(4):459-69. PubMed ID: 23262795
[TBL] [Abstract] [Full Text] [Related]
13. Expression of Bak and Bak/Mcl-1 ratio can predict photodynamic therapy outcome for oral verrucous hyperplasia and leukoplakia.
Yu CH; Chen HM; Lin HP; Chiang CP
J Oral Pathol Med; 2013 Mar; 42(3):257-62. PubMed ID: 22974427
[TBL] [Abstract] [Full Text] [Related]
14. Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and leukemia Group B 40101.
Shulman LN; Cirrincione CT; Berry DA; Becker HP; Perez EA; O'Regan R; Martino S; Atkins JN; Mayer E; Schneider CJ; Kimmick G; Norton L; Muss H; Winer EP; Hudis C
J Clin Oncol; 2012 Nov; 30(33):4071-6. PubMed ID: 22826271
[TBL] [Abstract] [Full Text] [Related]
15. Management of hairy cell leukemia variant.
Robak T
Leuk Lymphoma; 2011 Jun; 52 Suppl 2():53-6. PubMed ID: 21599606
[TBL] [Abstract] [Full Text] [Related]
16. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and leukemia Group B and Southwest Oncology Group.
Heinrich MC; Owzar K; Corless CL; Hollis D; Borden EC; Fletcher CD; Ryan CW; von Mehren M; Blanke CD; Rankin C; Benjamin RS; Bramwell VH; Demetri GD; Bertagnolli MM; Fletcher JA
J Clin Oncol; 2008 Nov; 26(33):5360-7. PubMed ID: 18955451
[TBL] [Abstract] [Full Text] [Related]
17. Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia.
Del Poeta G; Del Principe MI; Buccisano F; Maurillo L; Capelli G; Luciano F; Perrotti AP; Degan M; Venditti A; de Fabritiis P; Gattei V; Amadori S
Cancer; 2008 Jan; 112(1):119-28. PubMed ID: 17999417
[TBL] [Abstract] [Full Text] [Related]
18. Mitoxantrone for multiple sclerosis.
Martinelli Boneschi F; Rovaris M; Capra R; Comi G
Cochrane Database Syst Rev; 2005 Oct; (4):CD002127. PubMed ID: 16235298
[TBL] [Abstract] [Full Text] [Related]
19. High-dose therapy with peripheral blood stem cell transplantation for patients with relapsed or refractory Hodgkin's disease: long-term outcome and prognostic factors.
Neben K; Hohaus S; Goldschmidt H; Egerer G; Voso MT; Ho AD; Haas R
Ann Hematol; 2000 Oct; 79(10):547-55. PubMed ID: 11100744
[TBL] [Abstract] [Full Text] [Related]
20. The immunosuppression and potential for EBV reactivation of fludarabine combined with cyclophosphamide and dexamethasone in patients with lymphoproliferative disorders.
Lazzarino M; Orlandi E; Baldanti F; Furione M; Pagnucco G; Astori C; Arcaini L; Viglio A; Paulli M; Gerna G; Bernasconi C
Br J Haematol; 1999 Dec; 107(4):877-82. PubMed ID: 10606897
[TBL] [Abstract] [Full Text] [Related]
[Next]
